Pharmacokinetics and electrophysiological effects of verapamil in patients with paroxysmal supraventricular tachycardia.

DOI
  • KOIKE Yuichi
    First Department of Pharmacology and Hokkaido University, School of Medicine
  • SAKURAI Masayuki
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.
  • KATO Noriyoshi
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.
  • FUJITA Miri
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.
  • NISHINO Tetsuo
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.
  • FUJITA Kosuke
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.
  • SAITO Hideya
    First Department of Pharmacology and Hokkaido University, School of Medicine
  • YASUDA Hisakazu
    Department of Cardiovascular Medicine, Hokkaido University, School of Medicine.

この論文をさがす

抄録

Ten mg of verapamil was administered intravenously to eight patients with paroxysmal supraventricular tachycardia. After drug administration, investigation of the pharmacokinetics of verapamil was carried out, and the relationship between plasma verapamil concentration and its electrophysiological effects was studied. After verapamil administration, pharmacokinetic parameters were calculated using a two-compartment open model. Biological half-life ranged from 2.91 to 4.55 hours and apparent volume of distribution ranged from 1.28 to 3.18 L/kg. Total body clearance ranged from 216 to 733 ml/min.<BR>Verapamil significantly prolonged the AH interval but did not prolong the HV interval. The effective and the functional refractory period of the AV node (ERPAVN and FRPAVN) were also prolonged after verapamil administration. The antegrade echo zone and the supraventricular tachycardia zone were also narrowed in most patients. A concentration-dependent relationship between plasma verapamil andpercent increase of both ERPAVN and AH interval was observed.

収録刊行物

  • 臨床薬理

    臨床薬理 14 (3), 495-506, 1983

    一般社団法人 日本臨床薬理学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ